The role and research progress of microRNA in acute leukemia

doi:10.16138/j.1673-6087.2023.06.014

Abstract

CLC Number:

R733.7

HUANG Rong, LIU Jing’an, ZHU Yilin, SHI Xiaofeng. The role and research progress of microRNA in acute leukemia[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(06): 451-456.

Figures/Tables 2

References 53

[1]	Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group[J]. Br J Haematol, 1976, 33(4): 451-458. doi: 10.1111/bjh.1976.33.issue-4 URL
[2]	Yamashita M, Dellorusso PV, Olson OC, et al. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis[J]. Nat Rev Cancer, 2020, 20(7): 365-382. doi: 10.1038/s41568-020-0260-3 pmid: 32415283
[3]	Zhang Y, Zhou SY, Yan HZ, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1[J]. Sci Rep, 2016, 6: 19995. doi: 10.1038/srep19995 pmid: 26847520
[4]	Krivdova G, Voisin V, Schoof EM, et al. Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML[J]. Cell Rep, 2022, 38(10): 110481.
[5]	Zhang L, Nguyen LXT, Chen YC, et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance[J]. Nat Commun, 2021, 12(1): 6154. doi: 10.1038/s41467-021-26420-7 pmid: 34686664
[6]	Zhu B, Zhong W, Cao X, et al. Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice[J]. Sci Transl Med, 2022, 14(629): eabh2548.
[7]	Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia[J]. Proc Natl Acad Sci U S A, 2007, 104(50): 19971-19976. doi: 10.1073/pnas.0709313104 URL
[8]	Zhu B, Xi X, Liu Q, et al. MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4[J]. Am J Transl Res, 2019, 11(6):3384-3397. pmid: 31312352
[9]	Wang G, Yu X, Xia J, et al. MicroRNA-9 restrains the sharp increase and boost apoptosis of human acute myeloid leukemia cells by adjusting the Hippo/YAP signaling pathway[J]. Bioengineered, 2021, 12(1): 2906-2914. doi: 10.1080/21655979.2021.1915727 pmid: 34167441
[10]	Huang J, Xiao R, Wang X, et al. MicroRNA-93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2[J]. Int J Oncol, 2021, 59(4): 81. doi: 10.3892/ijo URL
[11]	Zhang R, Tang P, Wang F, et al. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway[J]. J Cell Biochem, 2019, 120(3): 4423-4432. doi: 10.1002/jcb.27728 pmid: 30367526
[12]	Fu Y, Li L, Hou J, et al. miR-139-5p regulates the proliferation of acute promyelocytic leukemia cells by targeting MNT[J]. J Oncol, 2021, 2021: 5522051.
[13]	Bao F, Zhang L, Pei X, et al. MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia[J]. PLoS One, 2021, 16(9): e0256995.
[14]	Zhang Y, Chu X, Wei Q. MiR-451 promotes cell apoptosis and inhibits autophagy in pediatric acute myeloid leukemia by targeting HMGB1[J]. J Environ Pathol Toxicol Oncol, 2021, 40(2): 45-53. doi: 10.1615/JEnvironPatholToxicolOncol.2021037139 pmid: 33822516
[15]	Tang YJ, Wu W, Chen QQ, et al. miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR[J]. BMC Cancer, 2022, 22(1): 909. doi: 10.1186/s12885-022-09996-1
[16]	Li SM, Zhao YQ, Hao YL, et al. Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2[J]. Eur Rev Med Pharmacol Sci, 2019, 23(3): 1203-1213.
[17]	Qin Y, Wang Y, Liu D. miR-4792 inhibits acute myeloid leukemia cell proliferation and invasion and promotes cell apoptosis by targeting Kindlin-3[J]. Oncol Res, 2020, 28(4): 357-369. doi: 10.3727/096504020X15844389264424 pmid: 32183929
[18]	Wang Z, Luo H, Fang Z, et al. MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis[J]. BMB Rep, 2018, 51(9): 444-449. pmid: 29764561
[19]	Zhang S, Zhang Q, Shi G, et al. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target[J]. Biomed Pharmacother, 2018, 97: 1189-1194. doi: S0753-3322(17)32015-2 pmid: 29136958
[20]	Wu F, Yin C, Qi J, et al. miR-362-5p promotes cell proliferation and cell cycle progression by targeting GAS7 in acute myeloid leukemia[J]. Hum Cell, 2020, 33(2): 405-415. doi: 10.1007/s13577-019-00319-4 pmid: 31925702
[21]	Wang CJ, Zou H, Feng GF. MiR-10b regulates the proli-feration and apoptosis of pediatric acute myeloid leukemia through targeting HOXD10[J]. Eur Rev Med Pharmacol Sci, 2018, 22(21): 7371-7378.
[22]	Li H, Tian X, Wang P, et al. MicroRNA-582-3p negatively regulates cell proliferation and cell cycle progression in acute myeloid leukemia by targeting cyclin B2[J]. Cell Mol Biol Lett, 2019, 24: 66. doi: 10.1186/s11658-019-0184-7 pmid: 31844417
[23]	Zhang L, Wang X, Wu J, et al. MiR-335-3p inhibits cell proliferation and induces cell cycle arrest and apoptosis in acute myeloid leukemia by targeting EIF3E[J]. Biosci Biotechnol Biochem, 2021, 85(9): 1953-1961. doi: 10.1093/bbb/zbab116 URL
[24]	Gao X, Fan S, Zhang X. MiR-1306-5p promotes cell proliferation and inhibits cell apoptosis in acute myeloid leukemia by downregulating PHF6 expression[J]. Leuk Res, 2022, 120: 106906. doi: 10.1016/j.leukres.2022.106906 URL
[25]	Zhou H, Jia X, Yang F, et al. miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6(CDK6)[J]. Bioengineered, 2021, 12(1): 4508-4519. doi: 10.1080/21655979.2021.1956400 URL
[26]	Chen X, Yang S, Zeng J, et al. miR-1271-5p inhibits cell proliferation and induces apoptosis in acute myeloid leukemia by targeting ZIC2[J]. Mol Med Rep, 2019, 19(1): 508-514.
[27]	Hu C, Yu M, Li C, et al. miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway[J]. Int J Biol Sci, 2020, 16(15): 2853-2867. doi: 10.7150/ijbs.44365 pmid: 33061801
[28]	Liang C, Li Y, Wang LN, et al. Up-regulated miR-155 is associated with poor prognosis in childhood acute lymphoblastic leukemia and promotes cell proliferation targeting ZNF238[J]. Hematology, 2021, 26(1): 16-25. doi: 10.1080/16078454.2020.1860187 pmid: 33357126
[29]	Wang H, He H, Yang C. miR-342 suppresses the pro-liferation and invasion of acute myeloid leukemia by targeting Naa10p[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 3671-3676. doi: 10.1080/21691401.2019.1596930 URL
[30]	Li C, Zhao T, Nie L, et al. MicroRNA-223 decreases cell proliferation, migration, invasion, and enhances cell apoptosis in childhood acute lymphoblastic leukemia via targeting Forkhead box O 1[J]. Biosci Rep, 2020, 40(10):BSR20200485.
[31]	Almeida RS, Costa E Silva M, Coutinho LL, et al. MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia[J]. Hematol Oncol, 2019, 37(1):103-112. doi: 10.1002/hon.2567 pmid: 30393877
[32]	Mansouri S, Khansarinejad B, Mosayebi G, et al. Alteration in expression of miR-32 and FBXW7 tumor suppressor in plasma samples of patients with T-cell acute lymphoblastic leukemia[J]. Cancer Manag Res, 2020, 12:1253-1259. doi: 10.2147/CMAR.S238470 pmid: 32110099
[33]	Zamani A, Fattahi Dolatabadi N, Houshmand M, et al. miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia[J]. Leuk Res, 2021, 109: 106643. doi: 10.1016/j.leukres.2021.106643 URL
[34]	Shahid S, Shahid W, Shaheen J, et al. Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia[J]. Sci Rep, 2021, 11(1): 22783.
[35]	Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA[J]. Nucleic Acids Res, 2011, 39(16): 7223-7233. doi: 10.1093/nar/gkr254 pmid: 21609964
[36]	Zhang B, Pei Z, Wang H, et al. Clinical value of serum miRNA in patients with acute promyelocytic leukemia[J]. J Oncol, 2022, 2022: 7315879.
[37]	Cao Y, Liu Y, Shang L, et al. Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia[J]. Int J Clin Oncol, 2022, 27(7): 1222-1232. doi: 10.1007/s10147-022-02161-5 pmid: 35536524
[38]	Yu AM, Tu MJ. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination[J]. Pharmacol Ther, 2022, 230: 107967. doi: 10.1016/j.pharmthera.2021.107967 URL
[39]	Yu AM, Choi YH, Tu MJ. RNA drugs and RNA targets for small molecules: principles, progress, and challenges[J]. Pharmacol Rev, 2020, 72(4): 862-898. doi: 10.1124/pr.120.019554 URL
[40]	Seto AG, Beatty X, Lynch JM, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proli-feration and survival in cutaneous T-cell lymphoma[J]. Br J Haematol, 2018, 183(3): 428-444. doi: 10.1111/bjh.2018.183.issue-3 URL
[41]	Vu TT, Stölzel F, Wang KW, et al. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia[J]. Leukemia, 2021, 35(7): 1933-1948. doi: 10.1038/s41375-020-01095-z pmid: 33262524
[42]	Durmaz B, Bagca BG, Cogulu O, et al. Antileukemic effects of anti-miR-146a, anti-miR-155, anti-miR-181a, and prednisolone on childhood acute lymphoblastic leukemia[J]. Biomed Res Int, 2021, 2021: 3207328.
[43]	Zhang H, Kang J, Liu L, et al. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy[J]. Aging (Albany NY), 2020, 12(20): 20111-20126.
[44]	Wang Z, Fang Z, Lu R, et al. MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide[J]. Oncol Res, 2019, 27(9): 1035-1042. doi: 10.3727/096504019X15528367532612 pmid: 30982490
[45]	Liu Y, Lei P, Qiao H, et al. miR-9 enhances the chemosensitivity of AML cells to daunorubicin by targeting the EIF5A2/MCL-1 axis[J]. Int J Biol Sci, 2019, 15(3): 579-586. doi: 10.7150/ijbs.29775 pmid: 30745844
[46]	Liu Y, Lei P, Qiao H, et al. MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2[J]. J Cell Biochem, 2020, 121(1): 385-393. doi: 10.1002/jcb.29192 pmid: 31222822
[47]	Bollaert E, Claus M, Vandewalle V, et al. MiR-15a-5p confers chemoresistance in acute myeloid leukemia by inhibiting autophagy induced by daunorubicin[J]. Int J Mol Sci, 2021, 22(10): 5153. doi: 10.3390/ijms22105153 URL
[48]	Vandewalle V, Essaghir A, Bollaert E, et al. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2[J]. J Cell Mol Med, 2021, 25(1): 575-585. doi: 10.1111/jcmm.16110 pmid: 33270982
[49]	Li Y, Zhang G, Wu B, et al. miR-199a-5p represses protective autophagy and overcomes chemoresistance by directly targeting DRAM1 in acute myeloid leukemia[J]. J Oncol, 2019, 2019: 5613417.
[50]	Liu H, Liu M, Zhang J, et al. Downregulated miR-130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin[J]. Mol Med Rep, 2020, 22(4): 2810-2816.
[51]	Cao YX, Wen F, Luo ZY, et al. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line[J]. J Cell Biochem, 2020, 121(10): 4022-4033. doi: 10.1002/jcb.v121.10 URL
[52]	Long S, Ren D, Zhong F, et al. Reversal of glucocorticoid resistance in acute lymphoblastic leukemia cells by miR-145[J]. PeerJ, 2020, 8: e9337. doi: 10.7717/peerj.9337 URL
[53]	Su YL, Wang X, Mann M, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo[J]. Blood, 2020, 135(3): 167-180. doi: 10.1182/blood.2019002045 URL

miRNA类型	作用结果	作用方式	作用靶基因	疾病类型	调控的细胞类型	信号通路	参考文献
9	抑癌	下调	CXCR4	AML	Kasumi-1		[8]
9	抑癌	下调		AML	HL-60	Hippo/YAP	[9]
93	促癌	上调	DAB2	AML	THP-1	PI3K/AKT	[10]
139-5p	抑癌	下调	TSPAN3	AML	HL-60、OCI-AML3	PI3K/AKT	[11]
139-5p	抑癌	下调	MNT	APL	NB4		[12]
20a-5p	抑癌	下调	PPP6C	AML	THP-1、U937		[13]
451	抑癌	下调	HMGB1	AML	HL-60、THP-1		[14]
29b-3p	抑癌	下调	HUR/ELAVL1	AML	K562、U937	NF-κB和JAK/STAT	[15]
504-3p	抑癌	下调	MTHFD2	AML	HL-60、THP-1		[16]
4792	抑癌	下调	KINDLIN3	AML	HL-60、Kg1a		[17]
204	抑癌	下调	HGF	AML	Kasumi-1、HL-60	HGF/c-Met	[18]
182-5p	促癌	上调	BCL2L12	AML	AML5、Kasumi-1		[19]
362-5p	促癌	上调	GAS7	AML	THP-1、HL-60		[20]
10b	促癌	上调	HOXD10	AML	HL-60		[21]
582-3p	抑癌	下调	CCNB2	AML	THP-1		[22]
335-3p	抑癌	下调	EIF3E	AML	THP-1、U937		[23]
1306-5p	促癌	上调	PHF6	AML	HL-60、K562		[24]
148a-3p	抑癌	下调	CDK6	AML	J111、KG-1a		[25]
1271-5p	抑癌	下调	ZIC2	AML	AML193、OCI-AML2		[26]
550-1	抑癌	下调	WWTR1	AML	MV4-11、Kasumi-1		[27]
155	促癌	上调	ZNF238	ALL	CEM-C1、Jurkat、MOLT-3、MOLT-4		[28]
342	抑癌	下调	Naa10p	AML	Kg1a、HL60		[29]
223	抑癌	下调	FOXO1	ALL	CCRF-CEM、NALM-6		[30]

miRNA类型	对药物敏感性的影响	影响的药物	疾病类型	调控的细胞类型	调控的靶基因	信号通路	参考文献
9	过表达后增强	柔红霉素	AML	THP-1、KG-1、 HL60、Kasumi-1	EIF5A2	EIF5A2/MCL-1	[45]
33b	过表达后增强	柔红霉素	AML	THP-1、KG-1、 Kasumi-1、HL-60	EIF5A2	EIF5A2/MCL-1	[46]
15a-5p	过表达后抑制	柔红霉素	AML	K562	ATG9A、ATG14、 GABARAPL1、SMPD1		[47]
15a-5p、21-5p	过表达后抑制	阿糖胞甘、柔红霉素	AML	K562、OCI-AML3	PDCD4、ARL2、BTG2		[48]
199a-5p	过表达后增强	多柔比星	AML	K562	DRAM1	DRAM1/自噬轴	[49]
146a、155、181a	沉默后增强	泼尼松龙	ALL	SUP-B15			[42]
130a	沉默后增强	多柔比星	AML	HL-60			[50]
let-7f	过表达后增强	多柔比星	AML	K562、K562/A02	ABCC5、ABCC10		[51]
145	过表达后增强	地塞米松	ALL	CEM-C1			[52]

The role and research progress of microRNA in acute leukemia

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 53

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	WEI Yihong, MA Zilin, ZHOU Duan, DENG Bing, TANG Jingyi. Analysis of influence factors on nucleic acid negative conversion time in SARS-CoV-2 Omicron infected patients over 60 years old [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(06): 377-382.
[2]	ZHAO Yajie, HE Qing, XU Zhihong. Impact of sarcopenia on quality of life and mobility in elderly patients with chronic obstructive pulmonary disease [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(06): 383-387.
[3]	LU Hao, XI Huimin, LI Lu, CAI Xun. Low-dose sorafenib combined with all-trans retinoic acid induces differentiation of acute myeloid leukemia cells with wild type Fms like tyrosine kinase 3 [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 428-434.
[4]	REN Jiayi, MI Jianqing. Progress of novel antibody-like drugs in treatment of acute B lymphoblastic leukemia [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 463-467.
[5]	GAO Caihong. Analysis of therapeutic efficacy of simplified diagnosis and treatment for outpatients with acute mild ischemic stroke in designated hospitals during the COVID-19 pandemic [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 385-389.
[6]	JIANG Tianyi, LIU Fujia, CHENG Wenyan, ZHAO Huijin, SHEN Yang. Recombinant human thrombopoietin in treatment of acute myeloid leukemia thrombocytopenia after chemotherapy: a real-world study [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 283-288.
[7]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 353-355.
[8]	LUO Dongfeng, YOU Jianhua, LI Xiaoyang, LI Junmin, ZHANG Yunxiang. Study on the efficacy and safety of different induction therapies in newly diagnosed elderly patients with acute myeloid leukemia and intolerance of intensive chemotherapy [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 220-226.
[9]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 253-255.
[10]	. [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 282-286.
[11]	HUANG Lei, YE Chenjing, WU Chao, XU Wenbin, YU Qing, LI Junmin, YAN Hua. Clinical observation of the combination therapy of azacitidine and venetoclax in newly diagnosed, elderly patients with acute myeloid leukemia [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(03): 178-182.
[12]	. [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(02): 131-133.